NYSEHealth CareHealth Care TechnologyS&P MidCap 400
$32.51
-0.67 (-2.02%)
Close of Nov 06, 2026 · end-of-day data
DOCS 8-K filings, explained
Every material Form 8-K Doximity has filed with the SEC since November 09, 2023, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Doximity reported fiscal second-quarter revenue of $174.5 million, up 4% from a year earlier, but net income fell to $34.7 million from $62.1 million and adjusted EBITDA declined 12% to $88.9 million. The company also gave fiscal third-quarter and updated full-year fiscal 2027 guidance, which shareholders can compare against these results.
Revenue of $174.5 million versus $168.5 million, up 4% year-over-year
Net income of $34.7 million versus $62.1 million; diluted EPS of $0.18 versus $0.31
Adjusted EBITDA of $88.9 million versus $100.8 million, down 12%; margin 50.9% versus 59.8%
Fiscal 2027 revenue guidance of $678 million to $683 million and adjusted EBITDA of $317 million to $325 million; third-quarter revenue guidance of $195 million to $196 million
Doximity reported fiscal first-quarter 2027 results for the quarter ended June 30, 2026, with revenue up 7% year-over-year but net income and adjusted EBITDA both lower than a year earlier. The company also gave revenue and adjusted EBITDA guidance for its fiscal second quarter and updated its full fiscal 2027 outlook, so shareholders face a mix of growth and declining profit.
Revenue was $156.6 million, up 7% from $145.9 million a year earlier.
Net income was $24.3 million, down from $53.3 million; diluted EPS was $0.13 versus $0.27.
Adjusted EBITDA was $74.8 million, down 6% from $79.8 million; free cash flow was $39.6 million, down 34%.
Guidance: fiscal Q2 revenue of $170 million to $171 million; fiscal 2027 revenue of $671 million to $681 million and adjusted EBITDA of $309 million to $329 million.
Doximity reported fiscal fourth-quarter 2026 revenue of $145.4 million, up 5%, but GAAP net income fell to $19.1 million from $62.5 million and adjusted EBITDA declined 6%. The company also gave fiscal 2027 revenue guidance of $664 million to $676 million and named Matthew Sonefeldt as chief financial officer and Steven L. Zatz, M.D. as president, both effective May 13, 2026.
Q4 revenue $145.4 million vs. $138.3 million; net income $19.1 million vs. $62.5 million; diluted EPS $0.10 vs. $0.31
Q4 adjusted EBITDA $65.8 million vs. $69.7 million; full-year fiscal 2026 revenue $644.9 million, up 13%
Fiscal 2027 guidance: revenue $664 million to $676 million; adjusted EBITDA $323 million to $335 million; fiscal Q1 revenue $151 million to $152 million
Matthew Sonefeldt becomes principal financial officer June 8, 2026; Siddharth Sitaram serves as interim PFO through June 7, 2026
Doximity disclosed that Chief Financial Officer Anna Bryson, who had been on medical leave, resigned on April 13, 2026, and that Chief Accounting Officer Siddharth Sitaram has served as interim principal financial and accounting officer since February 3, 2026. The company also reaffirmed its guidance for the fourth quarter and full fiscal year ending March 31, 2026, given on February 5, 2026, which matters to shareholders because it signals no change to prior expectations despite the leadership transition.
CFO Anna Bryson resigned; the company accepted her resignation on April 13, 2026
Siddharth Sitaram, Chief Accounting Officer, serves as interim principal financial and accounting officer, effective February 3, 2026
Company reaffirmed fourth quarter and full fiscal year 2026 guidance first given February 5, 2026
Company expects to update on the CFO search during its next earnings call
Doximity reported fiscal third-quarter revenue of $185.1 million, up 10% year-over-year, while GAAP net income fell to $61.6 million from $75.2 million. The company updated its full-year fiscal 2026 revenue and adjusted EBITDA guidance and authorized a new $500 million share repurchase program. Chief Financial Officer Anna Bryson is on a temporary medical leave, and Chief Accounting Officer Siddharth Sitaram has been named interim principal financial and accounting officer effective February 3, 2026.
Q3 revenue of $185.1 million, up 10%; GAAP diluted EPS of $0.31 versus $0.37 a year earlier
Adjusted EBITDA of $111.4 million, up 9%; non-GAAP diluted EPS of $0.46 versus $0.45
Fiscal 2026 revenue guidance updated to $642.5 million to $643.5 million; adjusted EBITDA guidance to $355.5 million to $356.5 million
CFO Anna Bryson on temporary medical leave; Siddharth Sitaram appointed interim principal financial officer effective February 3, 2026
Doximity reported fiscal 2026 second-quarter results for the three months ended September 30, 2025, with revenue up 23% year over year and net income rising to $62.1 million from $44.2 million. The company also set fiscal third-quarter guidance and updated its full-year fiscal 2026 revenue and adjusted EBITDA guidance, which the filing does not compare with prior figures.
Revenue of $168.5 million, up 23% from $136.8 million a year earlier
Diluted net income per share of $0.31, versus $0.22; operating cash flow of $93.9 million, up 37%
Fiscal third-quarter (ending December 31, 2025) guidance: revenue of $180 million to $181 million and adjusted EBITDA of $103 million to $104 million
Updated fiscal 2026 (ending March 31, 2026) guidance: revenue of $640 million to $646 million and adjusted EBITDA of $351 million to $357 million
Doximity said its General Counsel, Corporate Secretary, and Chief Compliance Officer, Jennifer Chaloemtiarana, will step down from those roles effective August 29, 2025. John Vaughan will take over all three positions on the same date, and she will stay on in an advisory capacity through November 17, 2025.
Jennifer Chaloemtiarana steps down as General Counsel, Corporate Secretary, and Chief Compliance Officer effective August 29, 2025
John Vaughan assumes all three positions on August 29, 2025
Chaloemtiarana remains employed in an advisory role through November 17, 2025, then receives post-employment payments under her August 10, 2020 offer letter
Doximity reported fiscal first-quarter 2026 results for the quarter ended June 30, 2025, with revenue up 15% year over year and net income rising to $53.3 million from $41.4 million. The company also issued fiscal second-quarter guidance and updated its full-year fiscal 2026 outlook, which shareholders can use to compare against future results.
Revenue of $145.9 million, up 15% from $126.7 million; adjusted EBITDA of $79.8 million, up 21%
Diluted net income per share of $0.27, versus $0.21; operating cash flow of $62.1 million, up 51%
Fiscal 2026 guidance updated to revenue of $628 million to $636 million and adjusted EBITDA of $341 million to $349 million
Doximity said co-founder Dr. Nathan Gross will step down as Chief Strategy Officer effective June 16, 2025, and become an advisor under an Independent Contractor Agreement dated June 13, 2025. The filing says he will receive no cash compensation for advisory services, and his existing equity awards will continue to vest through September 2025.
Dr. Nathan Gross notified the company on June 10, 2025 of his transition; the change takes effect June 16, 2025.
Advisor Agreement is dated June 13, 2025 and runs until terminated under its terms; no cash compensation will be paid.
RSU and option awards granted to Dr. Gross will continue to vest through September 2025.
The company expects to file the Advisor Agreement as an exhibit to its Form 10-Q for the quarter ending June 30, 2025.
Doximity reported fourth-quarter and fiscal 2025 results for the period ended March 31, 2025, with revenue, net income and cash flow all higher than a year earlier. The company also issued revenue and adjusted EBITDA guidance for the fiscal first quarter and full fiscal 2026, which shareholders can compare against these results.
Q4 revenue of $138.3 million, up 17% from $118.1 million; Q4 net income of $62.5 million versus $40.6 million
Fiscal 2025 revenue of $570.4 million, up 20%; net income of $223.2 million versus $147.6 million
Q4 diluted net income per share of $0.31 versus $0.20; Q4 free cash flow of $97.0 million, up 56%
Fiscal 2026 guidance: revenue of $619 million to $631 million and adjusted EBITDA of $333 million to $345 million
Doximity reported fiscal third-quarter 2025 results for the quarter ended December 31, 2024, with revenue of $168.6 million, up 25% year over year, and net income of $75.2 million, up from $48.0 million. The company also issued fourth-quarter guidance of $132.5 million to $133.5 million in revenue and updated its fiscal 2025 revenue guidance to $564.6 million to $565.6 million.
Q3 revenue of $168.6 million versus $135.3 million a year earlier, up 25%
Diluted net income per share of $0.37 versus $0.24; adjusted EBITDA of $102.0 million, up 39%
Q4 guidance: revenue of $132.5 million to $133.5 million; adjusted EBITDA of $62.5 million to $63.5 million
Fiscal 2025 guidance updated to revenue of $564.6 million to $565.6 million and adjusted EBITDA of $306.6 million to $307.6 million
Doximity reported fiscal second-quarter results for the period ended September 30, 2024, with revenue up 20% year-over-year and net income up 44%. The company also updated its full-year fiscal 2025 guidance, with revenue now expected at $535 million to $540 million, which shareholders will want to compare with the prior outlook.
Revenue of $136.8 million, up 20% from $113.6 million a year earlier
Net income of $44.2 million, up from $30.6 million; diluted EPS of $0.22 versus $0.15
Fiscal 2025 guidance: revenue $535 million to $540 million and adjusted EBITDA $274 million to $279 million; fiscal third-quarter revenue guidance of $152 million to $153 million
Restructuring and impairment charge of $2.3 million in the quarter, compared with $7.9 million a year earlier
Doximity reported results for the fiscal 2025 first quarter ended June 30, 2024, with revenue of $126.7 million, up 17% year-over-year, and net income of $41.4 million, up from $28.4 million. The company also issued guidance for the fiscal second quarter and full fiscal 2025, but the filing does not compare that guidance with any prior outlook. Operating cash flow fell 28% to $41.2 million, and the company repurchased $51.2 million of common stock during the quarter.
Revenue of $126.7 million, up 17% from $108.5 million a year earlier
Net income of $41.4 million, up from $28.4 million; diluted EPS of $0.21 versus $0.13
Adjusted EBITDA of $65.9 million, up 42%; operating cash flow of $41.2 million, down 28%
Fiscal 2025 revenue guidance of $514 million to $523 million; fiscal second quarter revenue guidance of $126.5 million to $127.5 million
Doximity reported fiscal fourth-quarter revenue of $118.1 million, up 6% year-over-year, with net income of $40.6 million, up 32%, and adjusted EBITDA of $56.4 million, up 15%. The company also gave fiscal 2025 revenue guidance of $506 million to $518 million and authorized a $500 million share repurchase program, which matters to shareholders because it signals profit growth alongside capital returns.
Q4 revenue of $118.1 million versus $111.0 million; subscription revenue of $112.7 million, up 9%
Fiscal 2024 revenue of $475.4 million, up 13%; net income of $147.6 million, up 31%
Guidance: fiscal Q1 2025 revenue of $119.5 million to $120.5 million; fiscal 2025 revenue of $506 million to $518 million
Board authorized up to $500 million of Class A stock repurchases on May 1, 2024, with no expiration date
Doximity reported fiscal third-quarter results for the quarter ended December 31, 2023, with revenue of $135.3 million, up 17%, net income of $48.0 million, up from $33.5 million, and adjusted EBITDA of $73.3 million, up 32%. The company also updated its fiscal 2024 guidance, with full-year revenue now expected between $473.3 million and $474.3 million, and CEO Jeff Tangney called the quarter a "beat and raise" on both top and bottom lines.
Revenue of $135.3 million, versus $115.3 million a year earlier, an increase of 17%.
Net income of $48.0 million, or $0.24 diluted per share, versus $33.5 million, or $0.16, a year earlier.
Fiscal fourth-quarter guidance: revenue of $115.9 million to $116.9 million and adjusted EBITDA of $50.5 million to $51.5 million.
Fiscal 2024 guidance updated to revenue of $473.3 million to $474.3 million and adjusted EBITDA of $224.5 million to $225.5 million.
Doximity reported fiscal second-quarter 2024 results for the period ended September 30, 2023, with revenue up 11% and net income up from the prior-year quarter. The company updated its fiscal 2024 revenue and adjusted EBITDA guidance and authorized a new $70 million share repurchase program, while operating cash flow fell 67% year-over-year.
Revenue of $113.6 million, up 11% from $102.2 million; net income of $30.6 million versus $26.3 million
Diluted net income per share of $0.15 versus $0.12; adjusted EBITDA of $54.2 million, up 18%
Operating cash flow of $12.9 million, down 67% from $39.5 million; restructuring expense of $7.9 million included in net income
Fiscal 2024 revenue guidance updated to $460 million to $472 million; board authorized up to $70 million in buybacks over the next 12 months
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Doximity filing is on SEC EDGAR ↗. 8-K briefs of other companies →